213 related articles for article (PubMed ID: 26512785)
1. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor.
Ureyen I; Karalok A; Tasci T; Turkmen O; Boran N; Tulunay G; Turan T
Int J Gynecol Cancer; 2016 Jan; 26(1):66-72. PubMed ID: 26512785
[TBL] [Abstract][Full Text] [Related]
2. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
4. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
[TBL] [Abstract][Full Text] [Related]
5. Clinical Predictors of Recurrence and Prognostic Value of Lymph Node Involvement in the Serous Borderline Ovarian Tumor.
Qian XQ; Hua XP; Wu JH; Shen YM; Cheng XD; Wan XY
Int J Gynecol Cancer; 2018 Feb; 28(2):279-284. PubMed ID: 29194193
[TBL] [Abstract][Full Text] [Related]
6. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
[TBL] [Abstract][Full Text] [Related]
9. New Pointers for Surgical Staging of Borderline Ovarian Tumors.
Bendifallah S; Nikpayam M; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
Ann Surg Oncol; 2016 Feb; 23(2):443-9. PubMed ID: 26442919
[TBL] [Abstract][Full Text] [Related]
10. Analysis of patients with stage IIIC endometrial cancer.
Turan T; Ureyen I; Duzguner I; Ozkaya E; Tasci T; Karalok A; Boran N; Kose MF; Tulunay G
Int J Gynecol Cancer; 2014 Jul; 24(6):1033-41. PubMed ID: 24905617
[TBL] [Abstract][Full Text] [Related]
11. Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study.
Bao L; Ding Y; Cai Q; Ning Y; Hu W; Xue X; Sun H; Hua K; Zhou X; Yi X
Int J Gynecol Cancer; 2016 Mar; 26(3):424-30. PubMed ID: 26825825
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
13. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
Anfinan N; Sait K; Ghatage P; Nation J; Chu P
Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
[TBL] [Abstract][Full Text] [Related]
14. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
15. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
16. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
17. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
[TBL] [Abstract][Full Text] [Related]
18. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
19. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study.
Guvenal T; Dursun P; Hasdemir PS; Hanhan M; Guven S; Yetimalar H; Goksedef BP; Sakarya DK; Doruk A; Terek MC; Saatli B; Guzin K; Corakci A; Deger E; Celik H; Cetin A; Ozsaran A; Ozbakkaloglu A; Kolusari A; Celik C; Keles R; Sagir FG; Dilek S; Uslu T; Dikmen Y; Altundag O; Ayhan A
Gynecol Oncol; 2013 Dec; 131(3):546-50. PubMed ID: 24016409
[TBL] [Abstract][Full Text] [Related]
20. Identification of factors that impact recurrence in patients with borderline ovarian tumors.
Chen X; Fang C; Zhu T; Zhang P; Yu A; Wang S
J Ovarian Res; 2017 Apr; 10(1):23. PubMed ID: 28376898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
